SYRS (Syros Pharmaceuticals) Cyclically Adjusted FCF per Share: $-31.32 (As of Sep. 2024)


SYRS Syros Pharmaceuticals Inc SYRS
12 GF Score
Price $0.00
View Full Analysis

What is Syros Pharmaceuticals Cyclically Adjusted FCF per Share?

Syros Pharmaceuticals SYRS 12 Cyclically Adjusted FCF per Share is $-31.32 as of Sep. 2024. GuruFocus rates SYRS with a GF Score™ of 12/100.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Syros Pharmaceuticals's adjusted free cash flow per share for the three months ended in Sep. 2024 was $-0.526. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $-31.32 for the trailing ten years ended in Sep. 2024.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2026-07-12), Syros Pharmaceuticals's current stock price is $0.0001. Syros Pharmaceuticals's Cyclically Adjusted FCF per Share for the quarter that ended in Sep. 2024 was $-31.32. Syros Pharmaceuticals's Cyclically Adjusted Price-to-FCF of today is .


Syros Pharmaceuticals  (OTCPK:SYRS) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Syros Pharmaceuticals Cyclically Adjusted FCF per Share Related Terms


Syros Pharmaceuticals Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Syros Pharmaceuticals's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Syros Pharmaceuticals Cyclically Adjusted FCF per Share Chart

Syros Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Syros Pharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -31.32

SYRS vs AFMDQ, BTAX, TRVN: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Syros Pharmaceuticals's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Syros Pharmaceuticals Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Syros Pharmaceuticals's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Syros Pharmaceuticals's Cyclically Adjusted Price-to-FCF falls into.


SYRS
12GF Score
Syros Pharmaceuticals Inc SYRS
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Syros Pharmaceuticals Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Syros Pharmaceuticals's adjusted Free Cash Flow per Share data for the three months ended in Sep. 2024 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=-0.526/315.3010*315.3010
=-0.526

Current CPI (Sep. 2024) = 315.3010.

Syros Pharmaceuticals Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201412 0.000 234.812 0.000
201503 -1.881 236.119 -2.512
201506 -24.153 238.638 -31.912
201509 -24.220 237.945 -32.094
201512 -33.310 236.525 -44.404
201603 -5.335 238.132 -7.064
201606 -44.914 241.018 -58.757
201609 -4.249 241.428 -5.549
201612 -4.239 241.432 -5.536
201703 -5.650 243.801 -7.307
201706 -4.739 244.955 -6.100
201709 -3.647 246.819 -4.659
201712 -4.039 246.524 -5.166
201803 -0.841 249.554 -1.063
201806 -4.285 251.989 -5.362
201809 -3.283 252.439 -4.101
201812 -4.155 251.233 -5.215
201903 -6.194 254.202 -7.683
201906 -4.660 256.143 -5.736
201909 -3.250 256.759 -3.991
201912 -4.372 256.974 -5.364
202003 -0.353 258.115 -0.431
202006 -2.936 257.797 -3.591
202009 -3.446 260.280 -4.174
202012 -6.139 260.474 -7.431
202103 -3.625 264.877 -4.315
202106 -4.276 271.696 -4.962
202109 -4.519 274.310 -5.194
202112 -3.687 278.802 -4.170
202203 -4.780 287.504 -5.242
202206 -4.119 296.311 -4.383
202209 -3.835 296.808 -4.074
202212 -1.567 296.797 -1.665
202303 -1.334 301.836 -1.394
202306 -0.802 305.109 -0.829
202309 -1.138 307.789 -1.166
202312 -0.629 306.746 -0.647
202403 -0.798 312.332 -0.806
202406 -0.755 314.175 -0.758
202409 -0.526 315.301 -0.526

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of $-31.32 mean?
Syros Pharmaceuticals (SYRS) has a Cyclically Adjusted FCF per Share of $-31.32 as of Sep. 2024. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Syros Pharmaceuticals and its competitors.
Is Syros Pharmaceuticals' Cyclically Adjusted FCF per Share too high?
Syros Pharmaceuticals' current Cyclically Adjusted FCF per Share is $-31.32. Overall, Syros Pharmaceuticals has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Syros Pharmaceuticals' Cyclically Adjusted FCF per Share compare to AFMDQ and BTAX?
Syros Pharmaceuticals' Cyclically Adjusted FCF per Share of $-31.32 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Syros Pharmaceuticals and its competitors. Syros Pharmaceuticals's current Cyclically Adjusted FCF per Share is $-31.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Syros Pharmaceuticals stock overvalued right now?
Syros Pharmaceuticals (SYRS) has a current Cyclically Adjusted FCF per Share of $-31.32. The current Cyclically Adjusted FCF per Share is $-31.32. Syros Pharmaceuticals' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Syros Pharmaceuticals (SYRS), the current Cyclically Adjusted FCF per Share is $-31.32 as of Sep. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Syros Pharmaceuticals Business Description

Address 35 CambridgePark Drive, 4th Floor, Cambridge, MA, USA, 02140
Syros Pharmaceuticals Inc is a biopharmaceutical company committed to developing new standards of care for the frontline treatment of patients with hematologic malignancies.
12GF Score

Get the complete analysis for SYRS

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price